A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
4CPS-339 Intrathecal administration of baclofen for the reduction of spasticity
2021
Section 4: Clinical pharmacy services
unpublished
Preserved Fulltext
therapy. In addition, it was prescribed in patients with a higher D-dimer. Doses and number of administrations were higher in the first peak. New scientific evidence led to the use of different concomitant treatments in the second peak: corticosteroids (second peak dexamethasone versus first peak methylprednisolone) and antiviral therapy (only remdesivir in the second peak). In the second peak, hospital and ICU stays were shorter, probably because tocilizumab was used in less serious patients.
doi:10.1136/ejhpharm-2021-eahpconf.171
fatcat:lu332zjphvh5bhokcpxd4t64x4